Abpro HoldingsABPO +3.66%9 EV-to-FCF is 0.49 as of Jun. 27, 2026. GuruFocus rates ABPO with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 333 Biotechnology companies, Abpro Holdings ranks better than 85.89% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Abpro Holdings's Enterprise Value is $-3.23 Mil.
Abpro Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.58 Mil. Therefore, Abpro Holdings's EV-to-FCF for today is 0.49.
The historical rank and industry rank for Abpro Holdings's EV-to-FCF or its related term are showing as below:
ABPO'
s EV-to-FCF Range Over the Past 10 Years
Min: -20.44 Med: -1.66 Max: 0.49
Current: 0.49
During the past 4 years, the highest EV-to-FCF of Abpro Holdings was 0.49. The lowest was -20.44. And the median was -1.66.
ABPO's EV-to-FCF is ranked better than 85.89% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs ABPO: 0.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abpro Holdings's PE Ratio (TTM) for today is calculated as:
Abpro Holdings's share price for today is $0.2249.
Abpro Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Abpro Holdings EV-to-FCF Related Terms
Abpro Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Abpro Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Abpro Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abpro Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abpro Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Abpro Holdings's EV-to-FCF falls into.
Abpro Holdings's current Enterprise Value is $-3.23 Mil.
Abpro Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abpro Holdings (ABPO) has a EV-to-FCF of 0.49 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abpro Holdings and its competitors. According to the industry distribution chart, Abpro Holdings ranks #47 out of 333 companies in the Biotechnology industry, placing it in the top 14.1%.
Is Abpro Holdings' EV-to-FCF too high?
Abpro Holdings' current EV-to-FCF is 0.49. The Biotechnology industry median EV-to-FCF is 14.65. Abpro Holdings' value of 0.49 is 96.7% below this industry median. Based on the distribution chart, Abpro Holdings ranks #47 out of 333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abpro Holdings has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Abpro Holdings' EV-to-FCF compare to LYRA and ATXI?
According to the Biotechnology industry distribution chart, Abpro Holdings ranks #47 out of 333 companies for EV-to-FCF. This places Abpro Holdings in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.65. Abpro Holdings' value of 0.49 is 96.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abpro Holdings's current EV-to-FCF of 0.49 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abpro Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abpro Holdings's current EV-to-FCF is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abpro Holdings stock overvalued right now?
Abpro Holdings (ABPO) has a current EV-to-FCF of 0.49. The current EV-to-FCF is 0.49 and 96.7% below the Biotechnology industry median of 14.65. Abpro Holdings' overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Abpro Holdings (ABPO), the current EV-to-FCF is 0.49 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. The company is focused on novel antibody constructs for immuno-oncology, ophthalmology, and infectious diseases. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, the company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
9GF Score
Get the complete analysis for ABPO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABPO has been successfully added to your 
